Clinical studies

NAD-HD is a double-blind randomized controlled multicenter trial investigating the effect of nicotinamide riboside supplement as a potential disease-modifying treatment in Huntington’s disease. The study has received funding from the KLINBEFORSK program, South-Eastern Norway Regional Health Authority and the Dam Foundation, and was launched in 2025 and is currently recruiting participants at Oslo University Hospital. A second study site will open in Bergen. Collaboration with patient organizations is also be central to the project.

Prospective study of parkinsonism in Oslo (PROSPOS) is a  longitudinal observational study tracking natural history, genetics, and biomarkers to understand disease mechanisms and facilitate personalized medicine in Parkinson’s disease and atypical parkinsonism, including multiple system atrophy (MSA). This study forms the basis of a number of ongoing PhD projects involving methods such as brain imaging using PET and MRI, studies of cerebrospinal fluid biomarkers, single-cell sequencing analyses and eye-tracking technology.

Enroll-HD is a global registry for Huntington’s disease including both symptomatic and presymptomatic gene carriers as well as family and community controls. Data is collected at annual visits. The study has included more than 30,000 participants worldwide. 

NADAPT is a double-blind randomized controlled trial investigating nicotinamide riboside supplement as a potential disease-modifying treatment in atypical parkinsonism, including multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The trial is led from the Haukeland University Hospital and the NeuroSysMed center. Lasse Pihlstrøm is site-PI at Oslo University Hospital

NOPARK was a double-blind randomized controlled trial investigating nicotinamide riboside supplement as a potential disease-modifying treatment in Parkinson’s disease. The trial was led from the Haukeland University Hospital and the NeuroSysMed center and was completed in 2025. Lasse Pihlstrøm was site-PI at Oslo University Hospital